N Haj Mohammad1, N Bernards2, M van Putten3, V E P P Lemmens4, M G H van Oijen5, H W M van Laarhoven6. 1. Department of Medical Oncology, Academic Medical Center, Amsterdam, The Netherlands; Department of Medical Oncology, University Medical Center Utrecht, The Netherlands. Electronic address: n.hajmohammad@umcutrecht.nl. 2. Department of Medical Oncology, Catharina Hospital, Eindhoven, The Netherlands; Department of Research, Netherlands Comprehensive Cancer Organisation, Utrecht, The Netherlands. 3. Department of Research, Netherlands Comprehensive Cancer Organisation, Utrecht, The Netherlands. 4. Department of Research, Netherlands Comprehensive Cancer Organisation, Utrecht, The Netherlands; Department of Public Health, Erasmus MC University Medical Center, Rotterdam, The Netherlands. 5. Department of Medical Oncology, Academic Medical Center, Amsterdam, The Netherlands; Department of Research, Netherlands Comprehensive Cancer Organisation, Utrecht, The Netherlands. 6. Department of Medical Oncology, Academic Medical Center, Amsterdam, The Netherlands.
Abstract
INTRODUCTION: Palliative systemic therapy has been shown to improve survival in metastatic oesophagogastric cancer. Administration of palliative systemic therapy in metastatic oesophagogastric cancer varies between hospitals. We aimed to explore the association between the annual hospital volume of oesophagogastric cancer patients and survival. METHODS: Patients diagnosed in the Netherlands between 2005 and 2013 with metastatic oesophagogastric cancer were identified in the Netherlands Cancer Registry. Patients were attributed according to three definitions of high volume: (1) high-volume incidence centre, (2) high-volume treatment centre and (3) high-volume surgical centre. Independent predictors for administration of palliative chemotherapy were evaluated by means of multivariable logistic regression analysis, and multivariable Cox proportional hazard regression analysis was performed to assess the impact of high-volume centres on survival. RESULTS: Our data set comprised 4078 patients with metastatic oesophageal cancer, and 5425 patients with metastatic gastric cancer, with a median overall survival of 20 weeks (95% confidence interval [CI] 19-21 weeks) and 16 weeks (95% CI 15-17 weeks), respectively. Patients with oesophageal cancer treated in a high-volume surgical centre (adjusted hazard ratio [HR] 0.80, 95% CI 0.70-0.91) and a high-volume treatment centre (adjusted HR 0.88, 95% CI 0.78-0.99) exhibited a decreased risk of death. For gastric cancer, patients treated in a high-volume surgical centre (adjusted HR 0.83, 95% CI 0.74-0.92) had a superior outcome. CONCLUSION: Improved survival in patients undergoing palliative systemic therapy for oesophagogastric cancer was associated with treatment in high-volume treatment and surgical centres. Further research should be implemented to explore which specific factors of high-volume centres are associated with improved outcomes.
INTRODUCTION: Palliative systemic therapy has been shown to improve survival in metastatic oesophagogastric cancer. Administration of palliative systemic therapy in metastatic oesophagogastric cancer varies between hospitals. We aimed to explore the association between the annual hospital volume of oesophagogastric cancerpatients and survival. METHODS:Patients diagnosed in the Netherlands between 2005 and 2013 with metastatic oesophagogastric cancer were identified in the Netherlands Cancer Registry. Patients were attributed according to three definitions of high volume: (1) high-volume incidence centre, (2) high-volume treatment centre and (3) high-volume surgical centre. Independent predictors for administration of palliative chemotherapy were evaluated by means of multivariable logistic regression analysis, and multivariable Cox proportional hazard regression analysis was performed to assess the impact of high-volume centres on survival. RESULTS: Our data set comprised 4078 patients with metastatic oesophageal cancer, and 5425 patients with metastatic gastric cancer, with a median overall survival of 20 weeks (95% confidence interval [CI] 19-21 weeks) and 16 weeks (95% CI 15-17 weeks), respectively. Patients with oesophageal cancer treated in a high-volume surgical centre (adjusted hazard ratio [HR] 0.80, 95% CI 0.70-0.91) and a high-volume treatment centre (adjusted HR 0.88, 95% CI 0.78-0.99) exhibited a decreased risk of death. For gastric cancer, patients treated in a high-volume surgical centre (adjusted HR 0.83, 95% CI 0.74-0.92) had a superior outcome. CONCLUSION: Improved survival in patients undergoing palliative systemic therapy for oesophagogastric cancer was associated with treatment in high-volume treatment and surgical centres. Further research should be implemented to explore which specific factors of high-volume centres are associated with improved outcomes.
Authors: Willemieke P M Dijksterhuis; Rob H A Verhoeven; Sybren L Meijer; Marije Slingerland; Nadia Haj Mohammad; Judith de Vos-Geelen; Laurens V Beerepoot; Theo van Voorthuizen; Geert-Jan Creemers; Martijn G H van Oijen; Hanneke W M van Laarhoven Journal: Gastric Cancer Date: 2020-01-11 Impact factor: 7.370
Authors: Joost Besseling; Jan Reitsma; Judith A Van Erkelens; Maike H J Schepens; Michiel P C Siroen; Cathelijne M P Ziedses des Plantes; Mark I van Berge Henegouwen; Laurens V Beerepoot; Theo Van Voorthuizen; Lia Van Zuylen; Rob H A Verhoeven; Hanneke van Laarhoven Journal: Cancers (Basel) Date: 2021-01-05 Impact factor: 6.639
Authors: Marieke Pape; Pauline A J Vissers; David Bertwistle; Laura McDonald; Marije Slingerland; Nadia Haj Mohammad; Laurens V Beerepoot; Jelle P Ruurda; Grard A P Nieuwenhuijzen; Paul M Jeene; Hanneke W M van Laarhoven; Rob H A Verhoeven Journal: Ther Adv Med Oncol Date: 2022-03-24 Impact factor: 8.168
Authors: Michael Mwachiro; Robert Parker; Justus Lando; Ian Simel; Nyail Chol; Sinkeet Ranketi; Robert Chepkwony; Linus Pyego; Caren Chepkirui; Winnie Chepkemoi; David Fleischer; Sanford Dawsey; Mark Topazian; Steve Burgert; Russell White Journal: Endosc Int Open Date: 2022-04-14
Authors: Willemieke P M Dijksterhuis; Maarten J Pruijt; Stephanie O van der Woude; Remy Klaassen; Sophie A Kurk; Martijn G H van Oijen; Hanneke W M van Laarhoven Journal: J Cachexia Sarcopenia Muscle Date: 2019-01-21 Impact factor: 12.910
Authors: Judith de Vos-Geelen; Sandra Me Geurts; Margreet van Putten; Liselot Bj Valkenburg-van Iersel; Heike I Grabsch; Nadia Haj Mohammad; Frank Jp Hoebers; Chantal V Hoge; Paul M Jeene; Evelien Jm de Jong; Hanneke Wm van Laarhoven; Tom Rozema; Marije Slingerland; Vivianne Cg Tjan-Heijnen; Grard Ap Nieuwenhuijzen; Valery Epp Lemmens Journal: World J Gastroenterol Date: 2019-12-21 Impact factor: 5.742
Authors: Sungjin Kim; Timothy P DiPeri; Michelle Guan; Veronica R Placencio-Hickok; Haesoo Kim; Jar-Yee Liu; Andrew Hendifar; Samuel J Klempner; Ryan Nipp; Alexandra Gangi; Miguel Burch; Kevin Waters; May Cho; Joseph Chao; Katelyn Atkins; Mitchell Kamrava; Richard Tuli; Jun Gong Journal: World J Gastrointest Surg Date: 2020-09-27